NovaBay [NBY] vs Third Harmonic Bio [THRD] Detailed Stock Comparison

NovaBay Pharmaceuticals, Inc.

NYSE
Loading...

Third Harmonic Bio, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: NovaBay Pharmaceuticals, Inc. wins in 6 metrics, Third Harmonic Bio, Inc. wins in 6 metrics, with 2 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric NovaBay Pharmaceuticals, Inc. Third Harmonic Bio, Inc. Better
P/E Ratio (TTM) 0.04 12.46 NovaBay Pharmaceuticals, Inc.
Price-to-Book Ratio N/A 0.89 N/A
Debt-to-Equity Ratio -0.03 1.10 Third Harmonic Bio, Inc.
PEG Ratio -2.38 0.17 Third Harmonic Bio, Inc.
EV/EBITDA -5.95 0.40 Third Harmonic Bio, Inc.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) 350.10% 0.00% NovaBay Pharmaceuticals, Inc.
EBITDA Margin (TTM) 350.10% N/A N/A
Return on Equity 95.53% -19.94% NovaBay Pharmaceuticals, Inc.
Return on Assets (TTM) -76.11% -14.60% Third Harmonic Bio, Inc.
Free Cash Flow (TTM) $-8.43M $-34.51M NovaBay Pharmaceuticals, Inc.
1-Year Return -53.82% -53.82% Tie
Enterprise Value $45.09M $-25.82M NovaBay Pharmaceuticals, Inc.
Revenue per Share (TTM) $0 N/A N/A
Earnings per Share (Diluted) $-28.50 $-1.24 Third Harmonic Bio, Inc.
Beta (Stock Volatility) 0.16 2.13 NovaBay Pharmaceuticals, Inc.
Short % of Float 9.79% 5.17% Third Harmonic Bio, Inc.

NovaBay Pharmaceuticals, Inc. vs Third Harmonic Bio, Inc. Stock Performance Analysis

Loading Price Chart...

NBY
THRD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NovaBay Pharmaceuticals, Inc.0.87%-17.14%-11.45%-21.62%-78.11%-96.05%
Third Harmonic Bio, Inc.0.00%0.00%-1.28%4.47%56.40%56.40%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NovaBay Pharmaceuticals, Inc.-53.82%-98.79%-99.97%-99.99%-100.00%-100.00%
Third Harmonic Bio, Inc.-53.82%-70.11%-70.11%-70.11%-70.11%-70.11%

Performance & Financial Health Analysis: NovaBay Pharmaceuticals, Inc. vs Third Harmonic Bio, Inc.

MetricNBYTHRD
Market Information
Market Cap i$34.35M$242.79M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i186,830173,590
90 Day Avg. Volume i486,346175,425
Last Close$1.16$5.38
52 Week Range$1.08 - $99.75$3.18 - $16.02
% from 52W High-98.84%-66.42%
All-Time High$130,156.25 (Oct 22, 2007)$24.59 (Oct 31, 2022)
% from All-Time High-100.00%-78.12%
Growth Metrics
Quarterly Revenue Growth-2.00%N/A
Quarterly Earnings Growth-1.23%N/A
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i3.50%0.00%
Return on Equity (TTM) i0.96%-0.20%
Debt to Equity (MRQ) i-0.031.10
Cash & Liquidity
Book Value per Share (MRQ)$-0.92$6.06
Cash per Share (MRQ)$0.30$6.02
Operating Cash Flow (TTM) i$2.70M$-41,687,000
Levered Free Cash Flow (TTM) i$-4,935,750$-28,660,250
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i$0.00N/A

Valuation & Enterprise Metrics Analysis: NovaBay Pharmaceuticals, Inc. vs Third Harmonic Bio, Inc.

MetricNBY (Apr 24, 2026)THRD (Aug 29, 2025)
Price Ratios
P/E Ratio (TTM) i0.0412.46
Forward P/E i-2.38-3.49
PEG Ratio i-2.380.17
Price to Sales (TTM) iN/AN/A
Price to Book (MRQ) iN/A0.89
Market Capitalization
Market Capitalization i$34.35M$242.79M
Enterprise Value i$45.09M$-25,821,452
Enterprise Value Metrics
Enterprise to Revenue iN/AN/A
Enterprise to EBITDA i-5.950.40
Risk & Other Metrics
Beta i0.162.13
Book Value per Share (MRQ) i$-0.92$6.06

Financial Statements Comparison: NovaBay Pharmaceuticals, Inc. vs Third Harmonic Bio, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBY (2025)THRD (2024)
Revenue/Sales i00
Cost of Goods Sold iN/AN/A
COGS % of Revenue i--
Gross Profit iN/AN/A
Gross Margin i--
Research & Development iN/A36.50M
Operating Income (EBIT) i-7.59M-58.87M
Operating Margin i--
EBITDA i-7.47M-58.82M
EBITDA Margin i--
Pre-Tax Income i-33.22M-45.47M
Pre-Tax Income % of Revenue i--
Income Tax iN/AN/A
Income Tax % of Revenue i--
Net Income (Profit) i-22.14M-45.47M
Profit Margin i--

Balance Sheet & Liquidity Metrics

MetricNBY (2025)THRD (2024)
Cash & Equivalents i7.96M285.06M
Total Current Assets i8.68M290.54M
Total Current Assets % of Revenue i--
Total Current Liabilities i1.14M7.11M
Total Current Liabilities % of Revenue i--
Long-Term Debt i287,0002.35M
Long-Term Debt % of Revenue i--
Total Shareholders Equity i-23.18M285.15M
Retained Earnings i-210.42M-159.69M
Retained Earnings % of Revenue i--
Property, Plant & Equipment i00

Cash Flow Statement Comparison

MetricNBY (2025)THRD (2024)
Operating Cash Flow i-33.33M-33.88M
Operating Cash Flow % of Revenue i--
Capital Expenditures iN/A-10,000
Free Cash Flow i-8.43M-34.51M
FCF Margin i--
Debt Repayment i-2.50MN/A
Common Stock Repurchase i-175,000N/A

Short Interest & Institutional Ownership Analysis

MetricNBYTHRD
Shares Short i333,1201.42M
Short Ratio i0.696.95
Short % of Float i9.79%5.17%
Shares Outstanding i25.22M44.86M
Float Shares i2.62M15.60M
% Held by Insiders i90.14%9.11%
% Held by Institutions i5.34%80.12%
% Held by Public i4.52%10.77%

Dividend Analysis & Yield Comparison: NovaBay Pharmaceuticals, Inc. vs Third Harmonic Bio, Inc.

MetricNBYTHRD
Last 12-Month Dividend i$0.00N/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i$0.00N/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i$0.00N/A
Ex-Dividend DateN/AN/A